The global sector for Behçet's disease therapeutics is experiencing a period of substantial growth, driven by an increasing prevalence of the disease and advancements in treatment options. The need for effective therapies to manage the multifaceted symptoms of Behçet's disease is propelling this expansion. Pharmaceutical companies are actively de